Get the Stockscreener App
17.73
1.72%
-0.31
Bausch Lomb Corp stock is traded at $17.73, with a volume of 335.60K.
It is down -1.72% in the last 24 hours and up +5.66% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$18.04
Open:
$17.8
24h Volume:
335.60K
Relative Volume:
0.83
Market Cap:
$6.33B
Revenue:
$5.21B
Net Income/Loss:
$-211.00M
P/E Ratio:
-28.69
EPS:
-0.6179
Net Cash Flow:
$861.30K
1W Performance:
-0.84%
1M Performance:
+5.66%
6M Performance:
+3.93%
1Y Performance:
+14.24%
1-Day Range:
$17.47
$17.96
1-Week Range:
$17.47
$18.46
52-Week Range:
$13.77
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.73 | 6.44B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
350.16 | 129.55B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.10 | 50.32B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
69.12 | 34.08B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
221.05 | 32.94B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
34.69 | 32.10B | 29.14B | 1.07B | 1.05B | 1.1956 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - Investing.com
Every patient in the study reached mid-range vision after cataract surgery. - Stock Titan
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)? - simplywall.st
Is Bausch + Lomb (TSX:BLCO) Strengthening Eye Care Leadership? - Kalkine Media
Bausch + Lomb Corporation - Menafn
Bausch + Lomb Survey Finds 14% Link Dry Eye to Menopause | BLCO Stock News - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Report: Analyzing a 9.10% Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - Yahoo Finance
H.C. Wainwright reiterates Bausch & Lomb stock rating on pipeline data - Investing.com
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack - Yahoo Finance
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - TradingView
Bausch + Lomb Corporation (BLCO) Stock Analysis: Exploring a 8.03% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Trading (BLCO) With Integrated Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine - Seeking Alpha
Did Bausch + Lomb’s (BLCO) Board Overhaul Amid Weak Returns Just Shift Its Investment Narrative? - simplywall.st
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Director Robert J. Chersi Granted 11,776 RSUs Under 2022 Incentive Plan - Kalkine Media
Bausch & Lomb (BLCO) director Barbara Trebbi receives 11,776-share RSU award - Stock Titan
Bausch & Lomb (BLCO) files Form 3 for new director Barbara Trebbi - Stock Titan
Bausch & Lomb (BLCO) director awarded 11,776 RSU-based common shares - Stock Titan
Bausch & Lomb (BLCO) director receives 11,776 RSU equity grant as compensation - Stock Titan
Bausch & Lomb Corp (BLCO) adds director Robert J. Chersi in Form 3 filing - Stock Titan
Bausch & Lomb Corp (BLCO) director Thomas Appio reports holding 27,583 shares - Stock Titan
Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics? - Kalkine Media
Senior VP Of Bausch + Lomb Sold 54% Of Their Shares - Moomoo
Bausch + Lomb (NYSE:BLCO) CAO Sells 52,900 Shares - marketbeat.com
Bausch & Lomb (BLCO) SVP Frederick Munsch sells 52,900 shares in August trade - Stock Titan
Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO? - simplywall.st
Form 8K Bausch & Lomb Corp For: 12 August By Investing.com - Investing.com South Africa
Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach Sells 18,559 Shares - GuruFocus
BLCO (BLCO) shareholder plans NYSE sale of 52,900 restricted shares - Stock Titan
Bausch + Lomb (NYSE:BLCO) Director Eschenbach Andrew Von Sells 12,500 Shares - MarketBeat
Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit - Stock Titan
Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock - MarketBeat
BLCO | Bausch + Lomb Corporation FinancialsIncome Statement - Quiver Quantitative
BLCO shareholder plans $887,885 stock sale (NYSE: BLCO) - Stock Titan
Bausch + Lomb Corporation (BLCO): Growth Potential and Analyst Ratings Point to an 11% Upside - DirectorsTalk Interviews
Bausch + Lomb Updates Board, Reaffirms 2026 Guidance - VisionMonday.com
Bausch + Lomb Corporation $BLCO Shares Bought by Sei Investments Co. - marketbeat.com
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bausch Lomb (BLCO) investor plans sale of 12,500 common shares - Stock Titan
Bausch & Lomb Corp (BLCO) awards 16,778 performance-based shares to executive - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP earns PSUs for 9,091 shares - Stock Titan
Bausch & Lomb Corp (BLCO) EVP awarded 20,973 PSUs after targets met - stocktitan.net
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):